Hodgkins Disease (HD) (DBCOND0071554)

Identifiers

Synonyms
Hodgkin’s disease / Hodgkin's disease NEC / Disease, Hodgkin / Hodgkins Disease / Hodgkin Disease / Hodgkin's Disease / Hodgkin lymphoma, unspecified / Hodgkin lymphoma (morphologic abnormality) / Hodgkin granuloma (morphologic abnormality) / Hodgkin's disease (disorder) / Hodgkin's disease NOS / Hodgkin's granuloma (disorder) / Hodgkin's granuloma / Hodgkin's paragranuloma / Hodgkin's disease, unspecified type / Hodgkin lymphoma / Lymphomas Hodgkin's disease / Hodgkin's lymphoma / Hodgkin lymphoma, nodular lymphocyte predominance (disorder) / Lymphogranulomatosis

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Chlorambucil
A chemotherapy agent used in the management of chronic lymphocytic leukemia and malignant lymphomas.
Cyclophosphamide
A nitrogen mustard used to treat lymphomas, myelomas, leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma.
Gallium chloride Ga-67
A radioactive isotope of gallium usually complexed with sodium citrate used to test for Hodgkin's disease, lymphoma, and bronchogenic carcinoma, and acute inflammatory lesions.
No drug targets
Gallium citrate Ga-67
A radiopharmaceutical agent used in the detection of the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma, as well as some acute inflammatory lesions.
Gemcitabine
A nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer.
Mechlorethamine
An antineoplastic agent used to treat Hodgkin's disease, lymphosarcoma, and chronic myelocytic or lymphocytic leukemia.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT00720603
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.Not AvailableNot Availableno_longer_available
NCT03138499
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,treatment3terminated
NCT02007811
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single VaccinationNo drug interventionstreatment1 / 2unknown_status
NCT01904175
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell TransplantNo drug interventionsNot AvailableNot Availablecompleted
NCT01890486
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenNo drug interventionsNot AvailableNot Availablerecruiting
NCT01702961
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's DiseasetreatmentNot Availablecompleted
NCT01315132
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological MalignanciesNo drug interventionstreatment2completed
NCT01188798
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignanciestreatment3completed
NCT01085058
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapydiagnostic2 / 3completed
NCT00975975
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancertreatment2completed
NCT00990587
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancytreatment1completed
NCT00990717
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignanciestreatment1completed
NCT00698685
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantationtreatment2terminated
NCT00667615
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)treatment1 / 2completed
NCT00606437
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) TransplantsNo drug interventionstreatment1completed
NCT00579917
Behavioral Intervention For BMT/SCT SurvivorsNo drug interventionsNot AvailableNot Availablecompleted
NCT00581815
Spectroscopy With Surface Coils and DecouplingNo drug interventionsdiagnostic1completed
NCT00551798
Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High GradeNo drug interventionsdiagnosticNot Availablecompleted
NCT00552825
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old ChildrenNo drug interventionsNot AvailableNot Availablecompleted
NCT00385788
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Diseasetreatment2completed
NCT00398177
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's DiseaseNo drug interventionsNot AvailableNot Availablerecruiting
NCT00176930
Stem Cell Transplant for Hematological MalignancytreatmentNot Availableterminated
NCT00163761
Efficacy Study of Outpatient Therapy for Lymphomatreatment2completed
NCT00163748
Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphomatreatment2completed
NCT00144677
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantationprevention2completed
NCT00129753
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Diseasetreatment2withdrawn
NCT00038818
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell TransplantationNo drug interventionstreatmentNot Availableterminated
NCT00001575
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid LeukemiaNo drug interventionstreatment1 / 2completed
NCT00001430
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in LymphomasNo drug interventionstreatment2completed
NCT02856646
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology PracticesNo drug interventionsNot AvailableNot Availablecompleted
NCT02639559
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignanciestreatment2completed
NCT01833884
Kinetic of Cytokines Decrease and Hodgkin Lymphoma PrognosticNo drug interventionsdiagnosticNot Availablecompleted
NCT01696461
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafortreatment2completed
NCT01555892
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALENo drug interventionstreatment1recruiting
NCT01527838
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood UnitNo drug interventionstreatment1completed
NCT01499147
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciestreatmentNot Availablecompleted
NCT01458288
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Diseasetreatment2completed
NCT01350245
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donortreatment2completed
NCT01221857
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignanciestreatment1 / 2completed
NCT01045382
MSC and HSC Coinfusion in Mismatched MinitransplantsNo drug interventionstreatment2terminated
NCT00952237
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSFtreatment1completed
NCT00935597
Host Dendritic Cells in Allograft PatientsNo drug interventionstreatment1unknown_status
NCT00718757
Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignanciestreatment1completed
NCT00685997
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant LymphomasNo drug interventionsNot AvailableNot Availablecompleted
NCT00598728
Quality of Life Among Survivors of Hodgkin LymphomaNo drug interventionsNot AvailableNot Availablecompleted
NCT00648037
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCTtreatmentNot Availablecompleted
NCT00608452
Prevalence+Significance of Paraneoplastic Autoantibodies in Many CancersNo drug interventionsNot AvailableNot Availablecompleted
NCT00569842
Investigation of the Cylex® ImmuKnow® AssayNo drug interventionsNot AvailableNot Availablecompleted
NCT00592111
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)treatment2completed
NCT00594308
In-Vivo Activated T-Cell Depletion to Prevent GVHDtreatmentNot Availableterminated
NCT00469729
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapytreatment2 / 3completed
NCT00460694
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological MalignanciesNo drug interventionstreatment1 / 2completed
NCT00423709
Allogeneic Blood Stem Cell TransplantationtreatmentNot Availablecompleted
NCT00396201
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Diseasetreatment2completed
NCT00368082
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)No drug interventionstreatment1active_not_recruiting
NCT00343564
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphomatreatment1 / 2completed
NCT00209014
Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Diseasetreatment2terminated
NCT00232440
Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/LymphomaNo drug interventionstreatment1 / 2completed
NCT00165438
Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based ChemotherapyNo drug interventionsNot AvailableNot Availablecompleted
NCT00165308
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease SurvivorspreventionNot Availablecompleted
NCT00131014
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesNo drug interventionsNot AvailableNot Availablerecruiting
NCT00136474
Amifostine for Head and Neck Irradiation in Lymphomatreatment2completed
NCT00144703
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantationprevention2completed
NCT00133367
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimustreatment2completed
NCT00147875
Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphomatreatment1 / 2completed
NCT02087657
Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell TransplantationNo drug interventionstreatmentNot Availableunknown_status
NCT01854567
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic MalignanciesNo drug interventionstreatment3completed
NCT01665768
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphomatreatment2completed
NCT01336712
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic DiseasesNo drug interventionstreatment2completed
NCT01321346
A Study Of Panobinostat In Children With Refractory Hematologic Malignanciestreatment1completed
NCT01283776
Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantationprevention2completed
NCT00924131
Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional TrialNo drug interventionsNot AvailableNot Availablecompleted
NCT00891592
Umbilical Cord Blood Transplant for Hematological MalignanciesNo drug interventionstreatment1completed
NCT00797472
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Diseasetreatment2unknown_status
NCT00683046
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignanciestreatment2completed
NCT00665314
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).treatment2completed
NCT00705250
Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphomatreatment2completed
NCT00691210
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignanciestreatment1completed
NCT00674427
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantNo drug interventionstreatment1terminated
NCT00652626
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Functionother1completed
NCT00597714
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell TransplantNo drug interventionstreatment2completed
NCT00587873
Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)treatment2completed
NCT00484874
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphomatreatment1 / 2completed
NCT00386217
Psychosocial Impact of Cancer-Related Female InfertilityNo drug interventionsNot AvailableNot Availablecompleted
NCT00284804
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Diseasetreatment2completed
NCT00256191
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignanciestreatment1completed
NCT00179816
Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumorstreatment1 / 2unknown_status
NCT00185692
Allogeneic Transplantation From Related Haploidentical Donorstreatment2completed
NCT00165425
Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal IrradiationNo drug interventionsdiagnosticNot Availableactive_not_recruiting
NCT00165412
Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT00150462
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignanciestreatment1completed
NCT00165269
Mantle Irradiation for Hodgkin's DiseaseNo drug interventionstreatment2completed
NCT00001830
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow TransplantsNo drug interventionstreatment1completed
NCT00000626
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Diseasetreatment2completed
NCT02200380
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairstreatment2terminated
NCT01100502
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)treatment3completed
NCT00649584
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignanciestreatment1terminated
NCT01026415
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)treatment1completed
NCT01196208
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001Not AvailableNot Availableno_longer_available
NCT01026233
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)treatment1completed
NCT00947856
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Studytreatment2completed
NCT00848926
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphomatreatment2completed
NCT01060904
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphomatreatment1completed
NCT00430846
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignanciestreatment1completed
NCT01500161
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Matchtreatment2terminated
NCT02070393
Breast-Sparing Proton Therapy for Hodgkin's DiseaseNo drug interventionstreatment0terminated
NCT00802113
Autologous and Allogeneic Transplant for Relapsed Lymphomatreatment1 / 2completed
NCT00713882
Health and Psychosocial Outcomes in Long-Term Lymphoma SurvivorsNo drug interventionsNot AvailableNot Availablecompleted
NCT00697684
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplanttreatment1completed
NCT01951885
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Preventionsupportive_care3completed
NCT00754286
A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With CancerNo drug interventionssupportive_careNot Availablecompleted
NCT00901225
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplanttreatment2completed
NCT00364676
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's DiseaseNo drug interventionstreatment1completed
NCT00571662
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplanttreatment2completed
NCT00764829
Blood Samples to Evaluate Biomarkers of Donor ChimerismNo drug interventionsNot AvailableNot Availablecompleted
NCT05255601
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphomatreatment1 / 2recruiting
NCT06120504
A Safety Study of SGN-35T in Adults With Advanced CancersNo drug interventionstreatment1recruiting
NCT00039676
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic CancerNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT01676805
Tissue Collection for Studies of Lymph CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT02682667
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsNo drug interventionsNot AvailableNot Availablerecruiting
NCT04998331
A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotinNo drug interventionsNot AvailableNot Availablecompleted
NCT06254495
A Safety Study of SGN-35C in Adults With Advanced CancersNo drug interventionstreatment1recruiting
NCT00903890
Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's LymphomaNo drug interventionsNot AvailableNot Availablecompleted
NCT03739502
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell TransplantNo drug interventionstreatment2recruiting
NCT01956084
Cytotoxic T Cells to Treat Relapsed EBV-positive LymphomaNo drug interventionstreatment1active_not_recruiting
NCT00724984
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphomatreatment1 / 2completed
NCT00779584
A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)treatment1completed
NCT01018979
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease PatientsNo drug interventionstreatment2completed
NCT01874054
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphomatreatment1 / 2completed
NCT00538551
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma CasesNo drug interventionsNot AvailableNot Availableunknown_status
NCT02567851
A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbiditytreatment2completed
NCT01555853
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphomatreatment1terminated
NCT00261677
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapytreatment3completed
NCT00916045
Pilot Study of Unrelated Cord Blood Transplantationtreatment2terminated
NCT04671693
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.No drug interventionspreventionNot Availablerecruiting
NCT04072393
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic CancersNo drug interventionssupportive_careNot Availableterminated
NCT02057185
Occupational Status and Hematological DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT00196885
Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Trainingtreatment2completed
NCT01188915
Personalised Program for Women Treated for Hodgkin DiseaseNo drug interventionspreventionNot Availableterminated
NCT02378337
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image QualityNo drug interventionsNot AvailableNot Availablecompleted
NCT00478959
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphomatreatment2completed
NCT01141959
Blood Samples to Identify Biomarkers in Haploidentical Graft RecipientsNo drug interventionsNot AvailableNot Availablecompleted
NCT01758042
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersNo drug interventionstreatmentNot Availablerecruiting
NCT02376699
Safety Study of SEA-CD40 in Cancer Patientstreatment1terminated
NCT00145613
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological MalignanciesNo drug interventionstreatment2completed
NCT02181218
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomastreatment1completed
NCT01158118
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donorstreatment2completed
NCT00733824
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphomatreatment1 / 2completed
NCT00241358
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignanciestreatment1 / 2completed
NCT00038558
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapytreatment3completed
NCT00514722
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic MalignanciesNo drug interventionstreatmentNot Availableterminated
NCT01858922
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12Atreatment2completed
NCT02979522
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphomatreatment1 / 2active_not_recruiting
NCT04629430
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCTNo drug interventionstreatmentNot Availablecompleted
NCT01764230
Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patientssupportive_careNot Availablecompleted
NCT00909948
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell TransplantNo drug interventionstreatment1terminated
NCT00025662
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDSNo drug interventionstreatment2completed
NCT00393380
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donorprevention2terminated
NCT06116929
Hodgkin's Disease and Chemotherapy Before 40 YearsNo drug interventionspreventionNot Availablenot_yet_recruiting
NCT00534989
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCTNo drug interventionstreatmentNot Availablecompleted
NCT05544968
CD30biAb-AATC for CD30+ MalignanciesNo drug interventionstreatment1 / 2not_yet_recruiting
NCT01343368
Preservation of Ovarian Function After Hematopoietic Cell Transplantsupportive_care2terminated
NCT00062868
LMP-specific T-cells for Patients With Relapsed EBV-positive LymphomaNo drug interventionstreatment1completed
NCT02927769
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatmenttreatment2completed
NCT02686346
Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICEtreatment1 / 2completed
NCT00444912
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)treatment2completed
NCT00039910
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of ThrombocytopeniaNo drug interventionsprevention3completed
NCT03755414
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantationtreatment1completed
NCT05188755
Fitness Assessment in Young Adults Recovered From LymphomaNo drug interventionsdiagnosticNot Availablecompleted
NCT01078350
Consent for Obtaining Additional Tissue at the Time of a Diagnostic BiopsyNo drug interventionsNot AvailableNot Availablecompleted
NCT03598608
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)treatment1 / 2recruiting
NCT02181738
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)treatment2completed
NCT01207921
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphomatreatment1completed
NCT00871702
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed DiseaseNo drug interventionstreatment1completed
NCT01745354
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)No drug interventionstreatment1terminated
NCT00186251
High Dose Chemotherapy Followed By PBSC Rescue for HDNo drug interventionstreatmentNot Availablecompleted
NCT00051597
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignanciestreatment1 / 2completed
NCT02663297
Administration of T Lymphocytes for Prevention of Relapse of LymphomasNo drug interventionstreatment1active_not_recruiting
NCT03527628
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapytreatment2unknown_status
NCT02287311
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)treatment1recruiting
NCT00398411
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cellsprevention3completed
NCT00636311
A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphomatreatment2completed
NCT01468311
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphomatreatment1 / 2terminated
NCT00540007
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphomatreatment2completed
NCT01716806
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)treatment2completed
NCT00188149
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PETNo drug interventionstreatment4unknown_status
NCT00388349
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Diseasetreatment2completed
NCT01135849
B-Receptor Signaling in CardiomyopathyNo drug interventionsNot AvailableNot Availablecompleted
NCT02867618
Carfilzomib and TGR-1202 in Treatment of R/R Lymphomatreatment1 / 2terminated
NCT00148018
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphomatreatment2terminated
NCT06093334
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HDNo drug interventionsdiagnosticNot Availablerecruiting
NCT00562224
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patientstreatment1completed
NCT00113724
Study of TPI 287 in Patients With Advanced Malignanciestreatment1completed
NCT04459416
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or LymphomaNo drug interventionstreatment3active_not_recruiting
NCT01969435
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphomatreatment2completed
NCT03942263
A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian FederationNo drug interventionsNot AvailableNot Availablecompleted
NCT02589548
Brazilian Prospective Hodgkin Lymphoma RegistryNo drug interventionsNot AvailableNot Availableunknown_status
NCT01490957
Functional Assessment of Cancer Therapy - Bone Marrow TransplantNo drug interventionsNot AvailableNot Availableunknown_status
NCT01195766
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphomatreatment2completed
NCT00534820
Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's DiseaseNo drug interventionsbasic_scienceNot Availablecompleted
NCT01121120
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patientssupportive_care2terminated
NCT03935282
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among SurvivorsNo drug interventionssupportive_careNot Availableactive_not_recruiting
NCT00058773
Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin DiseaseNo drug interventionstreatment1terminated
NCT00225173
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Diseasetreatment2terminated
NCT02104427
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patientstreatment2completed
NCT03838627
Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR)No drug interventionsNot AvailableNot Availablecompleted
NCT00275262
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantationtreatment2terminated
NCT02389101
Molecular and Whole-body MR Imaging in LymphomasNo drug interventionsdiagnosticNot Availablecompleted
NCT01149668
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancertreatment1completed
NCT00901069
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphomatreatment1completed
NCT01333046
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTALtreatment1active_not_recruiting
NCT02939014
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)treatment2completed
NCT00026208
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphomatreatment2completed
NCT02885038
Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic MalignaciesNo drug interventionsNot AvailableNot Availablecompleted